A denomyosis and endometriosis are associated with severe clinical symptoms like dysmenorrhea, cyclical/acyclical pelvic pain, painful defecation, urination, and intercourse. Also, infertility is associated with both manifestations. The disease dramatically impacts the quality of life and is associated with mental comorbidities like depression and anxiety disorders. Similar to endometriosis, it is a benign, estrogendependent disorder resulting in abnormal uterine bleeding and painful menses, as well as uterine enlargement 1 and can be associated with poor pregnancy outcomes. 2 It is a chronic estrogen-dependent inflammatory disease and affects around 10% of all women during their reproductive age. The economic burden of this disease is underestimated. So far, no causal treatment option is available, and patients suffer from high recurrence rates. 3,4 As adenomyosis is disease of high prevalence and high morbidity, which is at the same time underrepresented in research and clinical knowledge, furthering the medical evidence in this disease entity is of utmost importance for the successful treatment and clinical management.Current first line treatment options of adenomyosis can consist of symptomatic treatment using NSAIDs, such as ibuprofen or naproxen, but many patients benefit from treatment using levonorgestrel-releasing intrauterine devices, oral progestins, or combined oral contraceptive pills. Although hysterectomy is the definitive treatment for patients with completed childbearing, uterine wedge resection or laparoscopic excision can be offered as focal surgical treatment in patients with future desired fertility. 5 However, minimally invasive techniques, like microwave ablation, radiofrequency ablation, or in the article at hand focal MRIguided high intensity focal ultrasound (HIFU) are promising and less traumatic for the patients. Improvement rates of up to 80% are reported in the literature for dysmenorrhea, menstrual disorder, and anemia, while adverse effects are low. 6